Macular Edema News and Research

RSS

EC approves Regeneron’s EYLEA for treatment of wet AMD

Regeneron Pharmaceuticals, Inc. today announced that EYLEA (aflibercept) Injection has been approved by the European Commission for the treatment of patients with neovascular (wet) age-related macular degeneration (wet AMD).

27 Nov 2012

ThromboGenics receives FDA approval for Jetrea to treat symptomatic vitreomacular adhesion

On Oct. 17, the U.S. Food and Drug Administration approved Jetrea (ocriplasmin), the first drug approved to treat an eye condition called symptomatic vitreomacular adhesion (VMA).

19 Oct 2012

Quick, cheap eye scan can predict brain damage in people with multiple sclerosis

An inexpensive, five-minute eye scan can accurately assess the amount of brain damage in people with the debilitating autoimmune disorder multiple sclerosis (MS), and offer clues about how quickly the disease is progressing, according to results of two Johns Hopkins studies.

19 Oct 2012

Ranibizumab improves driving prospects for AMD patients

Treatment with ranibizumab can preserve and even improve the perceived driving ability of patients with age-related macular degeneration, show the results of two randomized trials.

10 Oct 2012

Ranibizumab injections keep those with AMD driving longer

The advanced neovascular, or “wet,” form of age-related macular degeneration (AMD), left untreated, is the most common cause of vision loss among the elderly and a leading reason for their loss of driving privileges. But results of a new study, published in the online version of the journal Ophthalmology, suggest that monthly injections of ranibizumab improve eye chart test results required for a driver’s license, build driver confidence and keep those with AMD driving longer.

3 Oct 2012

pSivida reports revenues of $699,000 for fourth quarter 2012

pSivida Corp., a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced financial results for its fourth quarter and fiscal year ended June 30, 2012.

25 Sep 2012

Aerpio Therapeutics commences AKB-9778 Phase 1b/2a trial in diabetic macular edema

Aerpio Therapeutics, a clinical-stage biopharmaceutical company developing innovative therapies for vascular diseases by targeting the Tie2 pathway, today announced that it has dosed the first patient in a Phase 1b/2a trial of AKB-9778 for the treatment of diabetic macular edema (DME).

20 Sep 2012

Age at diabetes onset linked to macular edema onset

Older age at onset of Type 1 diabetes significantly increases the risk for developing clinically significant macular edema, show study findings.

19 Sep 2012

Factors predictive of successful DME treatment revealed

The pretreatment central subfield thickness in the eyes of patients with diabetic macular edema is the strongest predictor of outcome after one year of treatment with ranibizumab, with a reduction linked to better visual acuity outcomes, report researchers.

14 Sep 2012

Ethypharm, Ampio enter definitive agreement to manufacture Zertane

Ampio Pharmaceuticals, Inc. (AMPE), a clinical stage biopharmaceutical company, with repurposed drugs and new molecular entities (NMEs) that treat inflammatory diseases, including osteoarthritis, diabetic macular edema (DME) and sexual dysfunction announced today that it has entered into a definitive agreement with Ethypharm Ltd for the manufacturing of Zertane, Ampio's drug for the treatment of premature ejaculation.

12 Sep 2012

Low HDL cholesterol ADVANCEs nephropathy risk in diabetes

People with diabetes are at a greater risk for the development or progression of diabetic nephropathy if they have low levels of high-density lipoprotein cholesterol, report researchers.

15 Aug 2012

Genentech receives FDA approval for Lucentis to treat diabetic macular edema

Genentech, a member of the Roche Group, today announced that Lucentis (ranibizumab injection) was approved by the U.S. Food & Drug Administration (FDA) for treatment of diabetic macular edema (DME), an eye condition in people with diabetes that causes blurred vision, severe vision loss and sometimes blindness

12 Aug 2012

Lucentis receives FDA approval for treatment of diabetic macular edema

The U.S. Food and Drug Administration today approved Lucentis (ranibizumab injection) for the treatment of diabetic macular edema (DME), a sight-threatening eye disease that occurs in people with diabetes.

10 Aug 2012

Regeneron reports total revenues of $304 million for second quarter 2012

Regeneron Pharmaceuticals, Inc. announced financial and operating results for the second quarter of 2012 and provided an update on development programs.

25 Jul 2012

FDA clears pSivida's IND for injectable sustained-release micro-insert to treat posterior uveitis

pSivida Corp., a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application to treat posterior uveitis with pSivida's injectable sustained-release micro-insert.

20 Jul 2012

Ampio announces advancement of NCE001 to preclinical development

Ampio Pharmaceuticals, Inc., a biopharmaceutical company developing repurposed drugs and new molecular entities (NMEs) that treat inflammatory diseases, including osteoarthritis, diabetic macular edema (DME) and sexual dysfunction and conducting clinical trials on its four lead drugs announced today the advancement of NCE001, from its proprietary methylphenidate derivatives family of compounds, to preclinical development for the treatment of glioblastoma multiforme, renal cell carcinoma and inflammatory breast cancer following the granting of multiple composition of matter and use patents in the USA, Canada, Europe and China.

17 Jul 2012

Ampio announces results from Optina trial on DME

Ampio Pharmaceuticals, Inc., a biopharmaceutical company developing innovative proprietary drugs for inflammation, eye disease, kidney disease, CNS disease, metabolic disease and male sexual dysfunction and conducting clinical trials on its three lead drugs (Ampion, Optina & Zertane), announced the significant results from their further analysis of its Optina trial on DME.

9 Jul 2012

Positive results from Salutaris’ episcleral brachytherapy trial on Wet AMD

Positive results from a trial of episcleral brachytherapy to treat Wet Age-related Macular Degeneration (Wet AMD) were presented today at the ARVO Drug and Gene Delivery to the Back of the Eye Conference.

15 Jun 2012

Thiazolidinedione drugs linked with increased risk of DME in patients with Type 2 diabetes

Treatment with glucose-lowering thiazolidinedione drugs in patients with Type 2 diabetes appears to be associated with an increased risk of diabetic macular edema (a complication that may affect vision) at 1-year and 10-year follow-up evaluations, according to a report published Online First by Archives of Internal Medicine, a JAMA Network publication.

12 Jun 2012

Ampio’s CRO completes Optina clinical trial for DME

Ampio Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, whose lead drugs treat inflammatory diseases, including osteoarthritis and complications of Diabetes Mellitus such as diabetic macular edema (and others) announced today that it's CRO has completed analysis of the primary end point in the Optina clinical trial for DME conducted at St Michael Diabetes Hospital in Toronto Canada.

11 Jun 2012